VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with one of the broadest tissue distributions and most diverse functional profiles of any peptide in biology. Originally named for its vasodilatory effects on intestinal blood vessels, VIP is now recognized as a central regulatory signal for the immune system, GI motility, circadian biology, pulmonary function, and neuroprotection — acting through VPAC1 and VPAC2 receptors expressed in virtually every tissue.

Multi-System Receptor Distribution

VPAC1 and VPAC2 receptors are G-protein-coupled receptors that activate adenylyl cyclase and increase intracellular cAMP. They are expressed in: - GI tract: Enteric neurons, smooth muscle, epithelial cells, immune cells - Immune system: T-cells, B-cells, macrophages, dendritic cells, mast cells - CNS: Hippocampus, suprachiasmatic nucleus (SCN), cortex, astrocytes - Lung: Pulmonary smooth muscle, pulmonary arterial endothelium - Heart: Cardiac myocytes and coronary vessels - Reproductive system: Uterine and ovarian tissue

This broad receptor distribution explains VIP's unusually wide-ranging effects — it is not a single-target compound but a systemic regulatory signal.

Immune Modulation: From Pro-Inflammatory to Regulatory

VIP is one of the most potent endogenous immunomodulators known. Its primary effect is shifting immune responses from pro-inflammatory Th1 toward anti-inflammatory Th2 and regulatory T-cell (Treg) phenotypes: - Reduces Th1 cytokines: IFN-γ, IL-2, TNF-α - Increases Th2 cytokines: IL-4, IL-5, IL-10 - Promotes regulatory T-cell differentiation and expansion - Inhibits activated macrophage pro-inflammatory cytokine production - Suppresses NF-κB in activated immune cells

These immunomodulatory effects make VIP theoretically relevant for autoimmune conditions, chronic inflammatory diseases, and MCAS (Mast Cell Activation Syndrome), where it reduces mast cell degranulation.

Gastrointestinal Effects

VIP is co-released with acetylcholine from non-adrenergic, non-cholinergic (NANC) enteric neurons and serves as a key regulator of GI function: - Relaxes GI smooth muscle — important for normal intestinal peristalsis and prevention of spasms - Stimulates intestinal epithelial chloride secretion and water transport - Protects gastric mucosa from acid damage (cytoprotective) - Regulates sphincter function in the GI tract - VIP deficiency in enteric neurons is associated with motility disorders

Neuroprotective Applications

VIP and its analog PACAP (pituitary adenylate cyclase-activating polypeptide) are among the most potent neuroprotective agents known in preclinical research: - Protects dopaminergic neurons in Parkinson's disease models - Reduces amyloid beta toxicity in Alzheimer's models - Promotes neurotrophic factor (BDNF, GDNF) expression - Protects neurons from excitotoxicity and oxidative stress - Anti-apoptotic in neurons through VPAC2 receptor / cAMP / PKA pathway

Circadian Biology

VIP is the primary neurotransmitter of the suprachiasmatic nucleus (SCN) — the brain's master circadian clock. VPAC2 receptor signaling synchronizes cellular circadian oscillators across the body to the central pacemaker. VIP deficiency in the SCN leads to arrhythmic circadian outputs, and VIP administration can help reset disrupted circadian rhythms in certain contexts.

Pulmonary Arterial Hypertension

VIP has been studied in Phase 2 trials for pulmonary arterial hypertension (PAH). Its pulmonary vasodilatory effects through VPAC1/VPAC2 on pulmonary vascular smooth muscle reduce pulmonary arterial pressure. Phase 2 data showed improvements in pulmonary hemodynamics and 6-minute walk distance, though the compound has not progressed to approval.